FDA Demands Notices for 'Safe' Food Ingredients Now?
Published Date: 8/11/2026
Proposed Rule
Summary
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
GRAS Notices Become Mandatory
FDA proposes to require anyone who introduces a substance into interstate commerce under the GRAS provision of section 201(s) of the FD&C Act to submit a GRAS notice for human or animal food uses (including indirect additives such as from packaging). FDA estimates the present value of the rule's industry costs at about $89.6 million (3% discount, 10 years) and annualized costs of about $10.5 million (3% discount).
Time-Limited Streamlined Submission Option
The proposal includes a time-limited option allowing firms to submit a streamlined submission for certain uses of substances already in interstate commerce before the final rule's effective date; doing so would incur one-time per-manufacturer costs (including possible translation costs for non-English-speaking manufacturers).
Not Notifying May Trigger FDA Review Priority
FDA states that if the mandatory notification requirement is not met for a substance's intended use, FDA would consider that noncompliance when prioritizing substances for post-market review, potentially increasing the chance of FDA scrutiny or action for non-notified uses.
Greater Public Disclosure of GRAS Uses
The rule would increase public disclosure and transparency about substances claimed to be GRAS for human and animal foods, giving consumers, state regulators, and advocacy groups more information about what is being added to the food supply.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
2026-19656, Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D2 Inactive Bakers Yeast
The FDA just gave a thumbs-up to using vitamin D2 inactive baker's yeast as a safe way to add vitamin D2 to certain foods. This change helps food makers boost vitamin D in their products, starting September 25, 2026. If anyone has concerns, they have until October 26, 2026, to speak up—no extra costs or hassles expected!
Previous / Next Documents
Previous: 2026-16288, English Language Proficiency; Out of Service Criteria
The FMCSA wants to make sure truck drivers who don’t speak English well enough can be taken out of service to keep roads safer. This change affects all commercial drivers and aligns rules with current safety checks, making enforcement clearer and fairer. Comments on this proposal are open until October 9, 2026, with no new costs expected for drivers or companies.
Next: 2026-16314, Employer Contributions to Trump Accounts and Nondiscrimination Rules for Dependent Care Assistance Programs
The IRS is proposing new rules for employers who contribute to Trump accounts and dependent care assistance programs. These rules focus on making sure contributions are fair and don’t favor certain employees over others. Employers and employees involved should pay attention, as comments are due by September 25, 2026, and a public hearing is set for October 15, 2026.